Paradoxically elevated efavirenz concentrations in HIV/tuberculosis- coinfected patients with CYP2B6 516TT genotype on rifampin-containing antituberculous therapy

Awewura Kwara; Margaret Lartey; Kwamena W. Sagoe; Michael H. Court

doi:10.1097/QAD.0b013e3283427e05

Paradoxically elevated efavirenz concentrations in HIV/tuberculosis- coinfected patients with CYP2B6 516TT genotype on rifampin-containing antituberculous therapy

Awewura Kwara, Margaret Lartey, Kwamena W. Sagoe, Michael H. Court

Department of Medical Microbiology

Research output: Contribution to journal › Article › peer-review

50 Citations (Scopus)

Abstract

Some individuals have higher efavirenz plasma concentrations during rifampin-containing tuberculosis (TB) therapy, contrary to the expected induction effect of rifampin. Among HIV-infected patients without (n = 38) and with TB on rifampin-containing therapy (n = 18), we tested the hypothesis that drug-gene interaction may explain the highly variable drug interactions. Two-way analysis of variance revealed a significant interaction between CYP2B6 516G→T polymorphism and rifampin-containing therapy, suggesting that efavirenz dose adjustment may need to be individualized on the basis of the patient's genotype.

Original language	English
Pages (from-to)	388-390
Number of pages	3
Journal	AIDS
Volume	25
Issue number	3
DOIs	https://doi.org/10.1097/QAD.0b013e3283427e05
Publication status	Published - 28 Jan 2011

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1097/QAD.0b013e3283427e05

Cite this

@article{23769283c3204431b67c5a923b0af050,

title = "Paradoxically elevated efavirenz concentrations in HIV/tuberculosis- coinfected patients with CYP2B6 516TT genotype on rifampin-containing antituberculous therapy",

abstract = "Some individuals have higher efavirenz plasma concentrations during rifampin-containing tuberculosis (TB) therapy, contrary to the expected induction effect of rifampin. Among HIV-infected patients without (n = 38) and with TB on rifampin-containing therapy (n = 18), we tested the hypothesis that drug-gene interaction may explain the highly variable drug interactions. Two-way analysis of variance revealed a significant interaction between CYP2B6 516G→T polymorphism and rifampin-containing therapy, suggesting that efavirenz dose adjustment may need to be individualized on the basis of the patient's genotype.",

author = "Awewura Kwara and Margaret Lartey and Sagoe, \{Kwamena W.\} and Court, \{Michael H.\}",

year = "2011",

month = jan,

day = "28",

doi = "10.1097/QAD.0b013e3283427e05",

language = "English",

volume = "25",

pages = "388--390",

journal = "AIDS",

issn = "0269-9370",

publisher = "Lippincott Williams and Wilkins",

number = "3",

}

TY - JOUR

T1 - Paradoxically elevated efavirenz concentrations in HIV/tuberculosis- coinfected patients with CYP2B6 516TT genotype on rifampin-containing antituberculous therapy

AU - Kwara, Awewura

AU - Lartey, Margaret

AU - Sagoe, Kwamena W.

AU - Court, Michael H.

PY - 2011/1/28

Y1 - 2011/1/28

N2 - Some individuals have higher efavirenz plasma concentrations during rifampin-containing tuberculosis (TB) therapy, contrary to the expected induction effect of rifampin. Among HIV-infected patients without (n = 38) and with TB on rifampin-containing therapy (n = 18), we tested the hypothesis that drug-gene interaction may explain the highly variable drug interactions. Two-way analysis of variance revealed a significant interaction between CYP2B6 516G→T polymorphism and rifampin-containing therapy, suggesting that efavirenz dose adjustment may need to be individualized on the basis of the patient's genotype.

AB - Some individuals have higher efavirenz plasma concentrations during rifampin-containing tuberculosis (TB) therapy, contrary to the expected induction effect of rifampin. Among HIV-infected patients without (n = 38) and with TB on rifampin-containing therapy (n = 18), we tested the hypothesis that drug-gene interaction may explain the highly variable drug interactions. Two-way analysis of variance revealed a significant interaction between CYP2B6 516G→T polymorphism and rifampin-containing therapy, suggesting that efavirenz dose adjustment may need to be individualized on the basis of the patient's genotype.

UR - https://www.scopus.com/pages/publications/79551594988

U2 - 10.1097/QAD.0b013e3283427e05

DO - 10.1097/QAD.0b013e3283427e05

M3 - Article

C2 - 21150552

AN - SCOPUS:79551594988

SN - 0269-9370

VL - 25

SP - 388

EP - 390

JO - AIDS

JF - AIDS

IS - 3

ER -

Paradoxically elevated efavirenz concentrations in HIV/tuberculosis- coinfected patients with CYP2B6 516TT genotype on rifampin-containing antituberculous therapy

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this